erlotinib hydrochloride has been researched along with pazopanib in 10 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (pazopanib) | Trials (pazopanib) | Recent Studies (post-2010) (pazopanib) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,147 | 237 | 1,028 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mancuso, A; Sternberg, CN | 1 |
| Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B | 1 |
| Adjei, AA; Burris, HA; Dy, GK; Eckhardt, SG; Huff, A; Infante, JR; Jones, SF; Ma, WW; Novello, S; Ottesen, LH; Suttle, AB; Wang, Q | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D | 1 |
| Arbour, KC; Riely, GJ | 1 |
| Burris, HA; Daniel, DB; Finney, L; Gian, VG; Greco, FA; Hainsworth, JD; Heymach, JV; Lipman, AJ; Shih, KC; Spigel, DR; Waterhouse, DM | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
4 review(s) available for erlotinib hydrochloride and pazopanib
| Article | Year |
|---|---|
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
2 trial(s) available for erlotinib hydrochloride and pazopanib
| Article | Year |
|---|---|
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Demography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Quinazolines; Sulfonamides; Treatment Outcome | 2013 |
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Progression-Free Survival; Proteomics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2018 |
4 other study(ies) available for erlotinib hydrochloride and pazopanib
| Article | Year |
|---|---|
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line; Dogs; Erlotinib Hydrochloride; Indazoles; Male; Mice; Morpholines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2012 |
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |
Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Lung Neoplasms; Proteomics; Pyrimidines; Sulfonamides | 2018 |